



RaQualia
innovators for life

5-HT₄ Partial Agonist: RQ-00000009
Alzheimer's Disease Therapy
Worldwide Partnering Opportunity

1. Executive Summary

RQ-00000009 will be a disease-modifying medicine for Alzheimer's disease

- RQ-00000009 at 0.1, 0.3 and 1 mg/kg exhibited pro-cognitive activity in a rat object recognition test
- RQ-00000009 at 0.3 and 1 mg/kg, restored scopolamine-impaired spontaneous alteration in a rat model
- RQ-00000009 dose-dependently decreased brain cortex β -amyloid protein (A β 1-40 and A β 1-42) in Tg2576 mice after 3-week treatment
- RQ-00000009 increased Acetylcholine (ACh) release in rat hippocampus in microdialysis experiment

RQ-00000009 is ready for Phase 2 clinical testing

- In FIH studies, RQ-00000009 was well tolerated (0.1 to 80 mg), rapidly absorbed with a mean $T_{1/2}$ between 22.5 to 47.1 hours
- In a 14-day multiple dose study, RQ-00000009 was safe and well tolerated at doses of 10 mg QD, 20 mg QD and 20 mg BID
- Projected efficacy dose for AD therapy is 1 mg once-a-day

2. Table of Contents

Title	Slide No.
1. Table of Contents	2
2. Executive Summary	3
3. Product Concept	4
4. Unmet Medical Needs	5
5. Market Opportunity	6
6. Background Rationale	7
7. Mechanism of Action	8
8. Compound Attributes	10
8.1 Compound Information	11
8.2 Non-clinical Pharmacology	12
8.3 Non-clinical Pharmacokinetics	20
8.4 Non-clinical Safety	23
8.5 Clinical Studies	26
8.6 Prediction of Effective Dose in Human	28
8.7 Safety Margin in Human	29
9. Competitors	30
10. Appendix	31

弊社とのパートナーリングをご希望の方は「[お問い合わせ](#)」よりご連絡ください

ラクオリア創薬株式会社

Copyright RaQualia Pharma Inc. All Rights Reserved. 2011